These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28881380)

  • 41. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
    Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
    J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
    [No Abstract]   [Full Text] [Related]  

  • 46. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oophorectomy can reduce ovarian cancer risk in women with BRCA mutations: patients benefit from counseling, support.
    Printz C
    Cancer; 2013 Nov; 119(22):3897-8. PubMed ID: 24590900
    [No Abstract]   [Full Text] [Related]  

  • 49. Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.
    Safra T
    Womens Health (Lond); 2009 Sep; 5(5):543-53. PubMed ID: 19702453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
    Burling MJ; Gamet K; Eva L; Tan AL
    Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal.
    Tinelli A; Malvasi A; Leo G; Vergara D; Pisanò M; Ciccarese M; Chiuri VE; Lorusso V
    Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Medical treatment options in BRCA-associated cancers].
    Kahán Z
    Magy Onkol; 2020 Mar; 64(1):13-24. PubMed ID: 32181758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.
    Marchetti C; De Felice F; Palaia I; Perniola G; Musella A; Musio D; Muzii L; Tombolini V; Panici PB
    BMC Womens Health; 2014 Dec; 14():150. PubMed ID: 25494812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
    Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
    Trivers KF; Baldwin LM; Miller JW; Matthews B; Andrilla CH; Lishner DM; Goff BA
    Cancer; 2011 Dec; 117(23):5334-43. PubMed ID: 21792861
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PARP inhibitors in ovarian cancer: current status and future promise.
    Liu JF; Konstantinopoulos PA; Matulonis UA
    Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
    Darooei M; Poornima S; Salma BU; Iyer GR; Pujar AN; Annapurna S; Shah A; Maddali S; Hasan Q
    Tumour Biol; 2017 Feb; 39(2):1010428317694303. PubMed ID: 28231738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer.
    Tung N
    JAMA; 2011 Jun; 305(21):2211-20. PubMed ID: 21558506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.